<p>查尔斯·施瓦布信托公司在最近向证券交易委员会提交的 13F 表格中表示，在第三季度将其在雅培（NYSE:ABT - 免费报告）的持股增加了 109.8%。该公司在本季度购买了额外的 15,394 股后，持有 29,412 股这家医疗产品制造商的股票。根据其最近的 SEC 文件，查尔斯·施瓦布信托公司在雅培的持股价值为 3,939,000 美元。</p>
<p>获取 <strong>雅培</strong> 的提醒：</p>
<ul>
<li>ABBV 股票：250 美元可能是大幅第三季度盈利超预期后的新底部</li>
</ul>
<p>其他大型投资者最近也增加或减少了对该公司的持股。IMG Wealth Management Inc.在第二季度将其在雅培的股份增加了 759.1%。IMG Wealth Management Inc.现在拥有 189 股这家医疗产品制造商的股票，价值 26,000 美元，此前在上个季度又购买了 167 股。Anfield Capital Management LLC 在第二季度将其在雅培的股份增加了 81.3%。Anfield Capital Management LLC 现在拥有 232 股这家医疗产品制造商的股票，价值 32,000 美元，此前在此期间又购买了 104 股。Delos Wealth Advisors LLC 在第二季度购买了雅培的新股份，价值 32,000 美元。Curio Wealth LLC 在第二季度将其在雅培的股份增加了 15,250.0%。Curio Wealth LLC 现在拥有 307 股这家医疗产品制造商的股票，价值 42,000 美元，此前在此期间又购买了 305 股。最后，Pineridge Advisors LLC 在第二季度将其在雅培的持股增加了 34.6%。Pineridge Advisors LLC 现在拥有 315 股这家医疗产品制造商的股票，价值 43,000 美元，此前在上个季度又购买了 81 股。目前，75.18% 的股票由机构投资者和对冲基金持有。</p>
<h2>分析师设定新目标价</h2>
<p>几位股票分析师最近对该公司发布了报告。加拿大皇家银行在 10 月 16 日的研究报告中重申了 “跑赢大盘” 的评级，并将雅培的目标价设定为 147.00 美元。Weiss Ratings 在 12 月 15 日的研究报告中重新发布了对雅培的 “买入（b-）” 评级。瑞穗证券在 10 月 14 日的研究报告中将雅培的目标价从 135.00 美元上调至 140.00 美元，并给予该公司 “中性” 评级。雷蒙德·詹姆斯金融在 10 月 16 日的研究报告中将雅培的目标价从 141.00 美元上调至 146.00 美元，并给予该股票 “跑赢大盘” 评级。最后，Evercore ISI 在 10 月 15 日的研究报告中将雅培的目标价从 144.00 美元下调至 142.00 美元，并为该公司设定了 “跑赢大盘” 的评级。两位股票研究分析师对该股票给予了强烈买入评级，十七位给予了买入评级，四位对该公司的股票给予了持有评级。根据 MarketBeat 的数据，雅培目前的平均评级为 “适度买入”，平均目标价为 147.00 美元。</p>
<ul>
<li>雅培十月股价暴跌是买入信号</li>
</ul>
<p><strong>查看我们对 ABT 的最新股票分析</strong></p>
<h2>雅培股票表现</h2>
<p>ABT 的股票在周五开盘价为 125.45 美元。该公司的速动比率为 1.24，流动比率为 1.70，债务与股本比率为 0.23。雅培的十二个月低点为 110.86 美元，十二个月高点为 141.23 美元。该股票的市值为 2181.3 亿美元，市盈率为 15.72，市盈增长比率为 2.29，贝塔值为 0.72。该公司有 50 日移动平均线为 126.77 美元，200 日移动平均线为 130.24 美元。</p>
<ul>
<li>为什么雅培是 2025 年第二季度的买入：增长与收益</li>
</ul>
<p>雅培（NYSE:ABT - 获取免费报告）最近在 10 月 15 日宣布了其财报。该医疗产品制造商报告本季度每股收益为 1.30 美元，符合市场共识预期的 1.30 美元。雅培的净利润率为 31.88%，股本回报率为 17.60%。该公司在本季度的收入为 113.7 亿美元，而分析师预期为 114 亿美元。在去年同期，该公司每股收益为 1.21 美元。该公司的收入同比增长了 6.9%。雅培已将其 2025 财年的每股收益指导设定为 5.120-5.180。作为一个整体，股票研究分析师预测雅培将在当前财年发布 5.14 美元的每股收益。</p>
<h2>雅培增加股息</h2>
<p>该公司最近还宣布了一项季度股息，将于 2 月 13 日（星期五）支付。1 月 15 日的登记投资者将获得 0.63 美元的股息。这比雅培之前的季度股息 0.59 美元有所增加。这相当于每年 2.52 美元的股息，股息收益率为 2.0%。该股息的除息日期为 1 月 15 日（星期四）。雅培的股息支付比率（DPR）目前为 29.57%。</p>
<h2>关于雅培</h2>
<p>（免费报告）</p>
<p>雅培是一家全球医疗保健公司，总部位于伊利诺伊州的雅培公园，开发、制造和销售广泛的医疗产品和服务。雅培成立于 1888 年，通过多个业务领域运营，专注于诊断、医疗设备、营养品和成熟药品。该公司向医院、诊所、实验室、零售商和直接面向消费者的渠道提供旨在诊断、治疗和管理各种健康状况的产品。</p>
<p>在诊断方面，雅培提供实验室和现场检测平台及试剂，用于检测传染病、慢性病和生物标志物；其 Alinity 系列仪器和快速检测解决方案就是这一能力的例子。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票，胜过雅培</li>
<li>在投资中，下调评级意味着什么？</li>
<li>这三家银行在年末前上涨，但这种趋势会持续吗？</li>
<li>现在值得购买的三只巨型成长股</li>
<li>这三只飙升的股票刚刚获得标准普尔 500 指数的最终认可</li>
<li>什么是成长股及其投资</li>
<li>这只 ETF 在美联储降息后获得了重大助力</li>
</ul>
<p><strong>想看看其他对雅培持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取雅培（NYSE:ABT - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在雅培吗？</h2>
<p>在考虑雅培之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前立即购买的股票……而雅培并不在名单上。</p>
<p>虽然雅培目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

雅培

嘉信理财

<p>查尔斯·施瓦布信托公司在第三季度将其在雅培的持股增加了 109.8%，目前拥有 29,412 股，价值 394 万美元。这一举动是机构投资者调整在雅培股份的更广泛趋势的一部分。分析师对雅培设定了适度买入评级，目标价格为 147.00 美元。雅培最近的财报符合预期，净利润率为 31.88%，收入同比增长 6.9%</p>

<p>Charles Schwab Trust Co increased its position in Abbott Laboratories (NYSE:ABT - Free Report) by 109.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The firm owned 29,412 shares of the healthcare product maker's stock after purchasing an additional 15,394 shares during the quarter. Charles Schwab Trust Co's holdings in Abbott Laboratories were worth $3,939,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>查尔斯·施瓦布信托公司在最近向证券交易委员会提交的 13F 表格中表示，在第三季度将其在雅培（NYSE:ABT - 免费报告）的持股增加了 109.8%。该公司在本季度购买了额外的 15,394 股后，持有 29,412 股这家医疗产品制造商的股票。根据其最近的 SEC 文件，查尔斯·施瓦布信托公司在雅培的持股价值为 3,939,000 美元。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>雅培</strong> 的提醒：</p>
</div><ul>
<li>ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat</li>
</ul>
<div class="lb-trans"><ul>
<li>ABBV 股票：250 美元可能是大幅第三季度盈利超预期后的新底部</li>
</ul>
</div><p>Other large investors also recently added to or reduced their stakes in the company. IMG Wealth Management Inc. raised its stake in shares of Abbott Laboratories by 759.1% during the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker's stock worth $26,000 after buying an additional 167 shares during the last quarter. Anfield Capital Management LLC lifted its stake in shares of Abbott Laboratories by 81.3% in the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker's stock valued at $32,000 after purchasing an additional 104 shares during the period. Delos Wealth Advisors LLC bought a new position in shares of Abbott Laboratories in the 2nd quarter worth $32,000. Curio Wealth LLC grew its stake in shares of Abbott Laboratories by 15,250.0% during the second quarter. Curio Wealth LLC now owns 307 shares of the healthcare product maker's stock worth $42,000 after purchasing an additional 305 shares during the period. Finally, Pineridge Advisors LLC increased its holdings in Abbott Laboratories by 34.6% in the second quarter. Pineridge Advisors LLC now owns 315 shares of the healthcare product maker's stock valued at $43,000 after purchasing an additional 81 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他大型投资者最近也增加或减少了对该公司的持股。IMG Wealth Management Inc.在第二季度将其在雅培的股份增加了 759.1%。IMG Wealth Management Inc.现在拥有 189 股这家医疗产品制造商的股票，价值 26,000 美元，此前在上个季度又购买了 167 股。Anfield Capital Management LLC 在第二季度将其在雅培的股份增加了 81.3%。Anfield Capital Management LLC 现在拥有 232 股这家医疗产品制造商的股票，价值 32,000 美元，此前在此期间又购买了 104 股。Delos Wealth Advisors LLC 在第二季度购买了雅培的新股份，价值 32,000 美元。Curio Wealth LLC 在第二季度将其在雅培的股份增加了 15,250.0%。Curio Wealth LLC 现在拥有 307 股这家医疗产品制造商的股票，价值 42,000 美元，此前在此期间又购买了 305 股。最后，Pineridge Advisors LLC 在第二季度将其在雅培的持股增加了 34.6%。Pineridge Advisors LLC 现在拥有 315 股这家医疗产品制造商的股票，价值 43,000 美元，此前在上个季度又购买了 81 股。目前，75.18% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several equities analysts have recently issued reports on the company. Royal Bank Of Canada restated an &#34;outperform&#34; rating and set a $147.00 target price on shares of Abbott Laboratories in a research report on Thursday, October 16th. Weiss Ratings reissued a &#34;buy (b-)&#34; rating on shares of Abbott Laboratories in a research note on Monday, December 15th. Mizuho upped their target price on shares of Abbott Laboratories from $135.00 to $140.00 and gave the company a &#34;neutral&#34; rating in a research note on Tuesday, October 14th. Raymond James Financial lifted their price target on shares of Abbott Laboratories from $141.00 to $146.00 and gave the stock an &#34;outperform&#34; rating in a research report on Thursday, October 16th. Finally, Evercore ISI lowered their price objective on shares of Abbott Laboratories from $144.00 to $142.00 and set an &#34;outperform&#34; rating for the company in a research report on Wednesday, October 15th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, Abbott Laboratories currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $147.00.</p>
<div class="lb-trans"><p>几位股票分析师最近对该公司发布了报告。加拿大皇家银行在 10 月 16 日的研究报告中重申了 “跑赢大盘” 的评级，并将雅培的目标价设定为 147.00 美元。Weiss Ratings 在 12 月 15 日的研究报告中重新发布了对雅培的 “买入（b-）” 评级。瑞穗证券在 10 月 14 日的研究报告中将雅培的目标价从 135.00 美元上调至 140.00 美元，并给予该公司 “中性” 评级。雷蒙德·詹姆斯金融在 10 月 16 日的研究报告中将雅培的目标价从 141.00 美元上调至 146.00 美元，并给予该股票 “跑赢大盘” 评级。最后，Evercore ISI 在 10 月 15 日的研究报告中将雅培的目标价从 144.00 美元下调至 142.00 美元，并为该公司设定了 “跑赢大盘” 的评级。两位股票研究分析师对该股票给予了强烈买入评级，十七位给予了买入评级，四位对该公司的股票给予了持有评级。根据 MarketBeat 的数据，雅培目前的平均评级为 “适度买入”，平均目标价为 147.00 美元。</p>
</div><ul>
<li>Abbott Laboratories' October Price Plunge Is a Signal to Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>雅培十月股价暴跌是买入信号</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Analysis on ABT</strong></p>
<div class="lb-trans"><p><strong>查看我们对 ABT 的最新股票分析</strong></p>
</div><h2>Abbott Laboratories Price Performance</h2>
<div class="lb-trans"><h2>雅培股票表现</h2>
</div><p>Shares of ABT opened at $125.45 on Friday. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23. The stock has a market capitalization of $218.13 billion, a P/E ratio of 15.72, a P/E/G ratio of 2.29 and a beta of 0.72. The company has a 50 day moving average of $126.77 and a 200-day moving average of $130.24.</p>
<div class="lb-trans"><p>ABT 的股票在周五开盘价为 125.45 美元。该公司的速动比率为 1.24，流动比率为 1.70，债务与股本比率为 0.23。雅培的十二个月低点为 110.86 美元，十二个月高点为 141.23 美元。该股票的市值为 2181.3 亿美元，市盈率为 15.72，市盈增长比率为 2.29，贝塔值为 0.72。该公司有 50 日移动平均线为 126.77 美元，200 日移动平均线为 130.24 美元。</p>
</div><ul>
<li>Why Abbott Laboratories Is a Q2 2025 Buy: Growth &amp; Yield</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么雅培是 2025 年第二季度的买入：增长与收益</li>
</ul>
</div><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 EPS for the quarter, hitting the consensus estimate of $1.30. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.60%. The business had revenue of $11.37 billion during the quarter, compared to analysts' expectations of $11.40 billion. During the same quarter in the prior year, the company posted $1.21 earnings per share. The firm's revenue was up 6.9% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. As a group, equities research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 获取免费报告）最近在 10 月 15 日宣布了其财报。该医疗产品制造商报告本季度每股收益为 1.30 美元，符合市场共识预期的 1.30 美元。雅培的净利润率为 31.88%，股本回报率为 17.60%。该公司在本季度的收入为 113.7 亿美元，而分析师预期为 114 亿美元。在去年同期，该公司每股收益为 1.21 美元。该公司的收入同比增长了 6.9%。雅培已将其 2025 财年的每股收益指导设定为 5.120-5.180。作为一个整体，股票研究分析师预测雅培将在当前财年发布 5.14 美元的每股收益。</p>
</div><h2>Abbott Laboratories Increases Dividend</h2>
<div class="lb-trans"><h2>雅培增加股息</h2>
</div><p>The business also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Thursday, January 15th will be given a $0.63 dividend. This is an increase from Abbott Laboratories's previous quarterly dividend of $0.59. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date of this dividend is Thursday, January 15th. Abbott Laboratories's dividend payout ratio (DPR) is presently 29.57%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度股息，将于 2 月 13 日（星期五）支付。1 月 15 日的登记投资者将获得 0.63 美元的股息。这比雅培之前的季度股息 0.59 美元有所增加。这相当于每年 2.52 美元的股息，股息收益率为 2.0%。该股息的除息日期为 1 月 15 日（星期四）。雅培的股息支付比率（DPR）目前为 29.57%。</p>
</div><h2>About Abbott Laboratories</h2>
<div class="lb-trans"><h2>关于雅培</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.</p>
<div class="lb-trans"><p>雅培是一家全球医疗保健公司，总部位于伊利诺伊州的雅培公园，开发、制造和销售广泛的医疗产品和服务。雅培成立于 1888 年，通过多个业务领域运营，专注于诊断、医疗设备、营养品和成熟药品。该公司向医院、诊所、实验室、零售商和直接面向消费者的渠道提供旨在诊断、治疗和管理各种健康状况的产品。</p>
</div><p>In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.</p>
<div class="lb-trans"><p>在诊断方面，雅培提供实验室和现场检测平台及试剂，用于检测传染病、慢性病和生物标志物；其 Alinity 系列仪器和快速检测解决方案就是这一能力的例子。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Abbott Laboratories</li>
<li>What Does Downgrade Mean in Investing?</li>
<li>These 3 Banks Are Rallying Into Year-End, But Will It Continue?</li>
<li>3 Monster Growth Stocks to Buy Now</li>
<li>3 Surging Stocks Just Got the Ultimate Stamp of Approval From the S&amp;P 500</li>
<li>What Are Growth Stocks and Investing in Them</li>
<li>This ETF Caught a Major Tailwind After the Fed’s Rate Cut</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过雅培</li>
<li>在投资中，下调评级意味着什么？</li>
<li>这三家银行在年末前上涨，但这种趋势会持续吗？</li>
<li>现在值得购买的三只巨型成长股</li>
<li>这三只飙升的股票刚刚获得标准普尔 500 指数的最终认可</li>
<li>什么是成长股及其投资</li>
<li>这只 ETF 在美联储降息后获得了重大助力</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ABT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对雅培持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取雅培（NYSE:ABT - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在雅培吗？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑雅培之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前立即购买的股票……而雅培并不在名单上。</p>
</div><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然雅培目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

嘉信理财信托公司持有雅培 394 万美元的股票